Strategies to Improve Vaccines for the Neonate - Novel vaccine formulations can provide more effective immune protection to newborns. - BioPharm International


Strategies to Improve Vaccines for the Neonate
Novel vaccine formulations can provide more effective immune protection to newborns.

BioPharm International

27. Barlow PG, et al. The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system. J Leuko Biol. 2006(80):509–520.

28. Bowdish DM, Davidson DJ, Speert DP, Hancock RE. The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 kinase pathways in primary human monocytes. J Immunol. 2004(172):3758–3765.

29. Davidson DJ, et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T-cell polarization. J Immunol. 2004(172):1146–1156.

30. De Y, et al. LL-37, the neutrophils granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemo-attract human peripheral blood neutrophils, monocytes, and T-cells. J Experim Med. 2000(192):1069–1074.

31. Lau, YE, Bowdish DM, Cosseau C, Hancock RE, Davidson DJ. Apoptosis of airway epithelial cells: Human serum sensitive induction by the cathelicidin LL-37. Am J Respir Cell Mol Biol. 2006(34):399–409.

32. Mookherjee N, et al. Bovine and human cathelicidin cationic host defense peptides similarly suppress transcriptional responses to bacterial lipopolysaccharide. J Leukoc Biol. 2006(80):1563–1574.

33. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol. (2002)169:3883–3891.

34. Scott MG, Rosenberger CM, Gold MR, Finlay BB, Hancock RE. An alpha-helical cationic antimicrobial peptide selectively modulates macrophage responses to lipopolysaccharide and directly alters macrophage gene expression. J Immunol. 2000(165):3358–3365.

35. Lillard JW Jr., Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR. Mechanisms for induction of acquired host immunity by neutrophils peptide defensins. Proc Natl Acad Sci USA. 1999(96):651–656.

36. Tani K,et al. Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int Immunol. 2000(12):691–700.

37. Brogden KA, et al. Defensin-induced adaptive immunity in mice and its potential in preventing periodontal disease. Oral Microbiol Immunol. 2003(18):95–99.

38. Biragyn A, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science. 2002(298):1025–1029.

39. Biragyn A, Belyakov IM, Chow YH, Dimitrov DS, Berzofsky JA, Kwak LW. DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with pro-inflammatory chemo-attractants induce systemic and mucosal immune responses. Blood. 2002(100):1153–1159.

40. Allcock HR. Polyphoshazenes as new biomedical and bioactive material. New York: Marcel Dekker;1990.

41. McNeal MM, Rae MN, Ward RL. Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine. 1999(17):1573–1580.

42. Payne LG, Andrianov AK. Protein release from polyphosphazene matrices. Adv Drug Deliv Rev. 1998(31):185–196.

43. Wu Y, Wang X, Csencsits KL, Haddad A, Walters N, Pascual DW. M cell-targeted DNA vaccination. Proc Natl Acad Sci USA. 2001(98):9318–9323.

44. Mutwiri G, Gerdts V, Lopez M, Babiuk LA. Innate immunity and new adjuvants. Rev Sci Tech Off Int Epiz. 2007(26):147–156.

45. Mutwiri G, et al. Poly[di(sodium carboxylatoethylphenoxy)phos-
phazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine (In press).

blog comments powered by Disqus



NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here